Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases.
Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases.
复制标题
与匹配的颅外转移瘤相比，黑色素瘤脑转移瘤的t细胞含量和微血管密度较低。
DOI：
10.1007/s11060-020-03619-0
复制
发表时间：
2021-03
影响因子：
3.9
通讯作者：
Jilaveanu LB
中科院分区：
文献类型：
--
作者：
Weiss SA;Zito C;Tran T;Heishima K;Neumeister V;McGuire J;Adeniran A;Kluger H;Jilaveanu LB
尽管黑色素瘤脑转移（MBM）往往对全身治疗的反应与颅外转移一致，但人们对大脑和其他转移部位之间免疫细胞和血管内容物的差异知之甚少。在这里，我们研究了成对的脑内和脑外黑色素瘤转移中的浸润免疫细胞亚群和微血管密度（MVD）。配对的脑内和脑外肿瘤组织取自 1997 年至 2014 年间接受开颅手术的 37 名转移性黑色素瘤患者。构建了组织微阵列，使用定量免疫荧光定量肿瘤浸润 T 细胞、B 细胞和巨噬细胞含量、PD-L1 表达和 MVD 亚群。与匹配的脑外转移瘤相比，MBM 具有较低的 CD3+ (p = 0.01) 和 CD4+ (p = 0.003) T 细胞含量、较低的 MVD (p = 0.006) 以及较低的 CD8+ (p = 0.17) T 细胞含量趋势。 CD20+B 细胞或 CD68+巨噬细胞含量、肿瘤或基质 PD-L1 表达没有显着差异。脑内转移灶中的低 MVD (p = 0.008) 和高 CD68+巨噬细胞密度 (p = 0.04) 与首次 MBM 诊断后 1 年生存率改善相关。尽管身体和大脑对免疫调节药物的反应往往是一致的，但这些部位之间的 MVD 和 T 细胞含量存在差异。这些标志物的研究应纳入前瞻性治疗临床试验，以确定其预后和预测价值。
Although melanoma brain metastases (MBM) tend to respond to systemic therapy concordantly with extracranial metastases, little is known about differences in immune cell and vascular content between the brain and other metastatic sites. Here we studied infiltrating immune cell subsets and microvessel density (MVD) in paired intracerebral and extracerebral melanoma metastases. Paired intracerebral and extracerebral tumor tissue was obtained from 37 patients with metastatic melanoma who underwent craniotomy between 1997 and 2014. A tissue microarray was constructed to quantify subsets of tumor-infiltrating T-cell, B-cell, and macrophage content, PD-L1 expression, and MVD using quantitative immunofluorescence. MBM had lower CD3+ (p = 0.01) and CD4+ (p = 0.003) T-cell content, lower MVD (p = 0.006), and a trend for lower CD8+ (p = 0.17) T-cell content compared to matched extracerebral metastases. There were no significant differences in CD20+ B-cell or CD68+ macrophage content, or tumor or stroma PD-L1 expression. Low MVD (p = 0.008) and high CD68+ macrophage density (p = 0.04) in intracerebral metastases were associated with improved 1-year survival from time of first MBM diagnosis. Although responses to immune-modulating drugs in the body and the brain tend to be concordant, differences were found in MVD and T-cell content between these sites. Studies of these markers should be incorporated into prospective therapeutic clinical trials to determine their prognostic and predictive value.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
DOI：
10.1158/1078-0432.ccr-17-1555
发表时间：
2018-01-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Jilaveanu LB;Puligandla M;Weiss SA;Wang XV;Zito C;Flaherty KT;Boeke M;Neumeister V;Camp RL;Adeniran A;Pins M;Manola J;DiPaola RS;Haas NB;Kluger HM
通讯作者：
Kluger HM
DOI：
10.1016/s1470-2045(16)30053-5
发表时间：
2016-07
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Goldberg SB;Gettinger SN;Mahajan A;Chiang AC;Herbst RS;Sznol M;Tsiouris AJ;Cohen J;Vortmeyer A;Jilaveanu L;Yu J;Hegde U;Speaker S;Madura M;Ralabate A;Rivera A;Rowen E;Gerrish H;Yao X;Chiang V;Kluger HM
通讯作者：
Kluger HM
影响因子：
158.5
作者：
Robert, Caroline;Schachter, Jacob;Ribas, Antoni
通讯作者：
Ribas, Antoni
PD-1，PD-1配体的关联以及肿瘤免疫微环境的其他特征与抗PD-1治疗的响应。
DOI：
10.1158/1078-0432.ccr-13-3271
发表时间：
2014-10-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Taube JM;Klein A;Brahmer JR;Xu H;Pan X;Kim JH;Chen L;Pardoll DM;Topalian SL;Anders RA
通讯作者：
Anders RA